Commentary
| Rev Diabet Stud,
2005,
2(4):187-189 |
DOI 10.1900/RDS.2005.2.187 |
Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach
Damien Bresson, Matthias von Herrath
La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 10355 Science Center Drive, San Diego, California 92121, USA.
Address correspondence to: Matthias von Herrath, e-mail: matthias@liai.org
Abstract
n/a
Fulltext:
 HTML
,  PDF
(174KB)
This article has been cited by other articles:
|
Induction of chimerism permits low-dose islet grafts in the liver or pancreas to reverse refractory autoimmune diabetes
Zhang C, Wang M, Racine JJ, Liu H, Lin CL, Nair I, Lau J, Cao YA, Todorov I, Atkinson M, Zeng D
Diabetes 2010. 59(9):2228-2236
|
|
|
Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis
Czaja AJ, Manns MP
Gastroenterology 2010. 139(1):58-72
|
|
|
"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?
Sia C, Weinem M
Rev Diabet Stud 2006. 3(4):156-160
|
|
|
